This year’s top stories on Duchenne muscular dystrophy (DMD ... A histone deacetylase inhibitor, givinostat has shown in clinical trials to improve functional outcomes like stair-climbing ...

UC Davis Health has premiered a new documentary on a family’s urgent journey across the globe to get their toddler in a clinical trial for patients with Duchenne Muscular Dystrophy, or DMD.

An estimated 1 in 8,000 individuals, or 870,000 people worldwide, are affected by Facioscapulohumeral muscular dystrophy ...

A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for ...

Irodanoprost is under clinical development by Mesentech and currently in Phase I for Duchenne Muscular Dystrophy.

Patients with Duchenne muscular dystrophy now have new hope with gene ... Mason received the multi-million dollar dose as part of a clinical trial. Now it’s Dawson’s turn.

Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and ...

application to initiate the CONNECT2-EDO51 clinical trial in patients with Duchenne muscular dystrophy (DMD). The FDA indicated they will provide an official clinical hold letter to the Company ...

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy -Company continues to advance PGN-EDO51 in ...

Wedbush initiated coverage on Solid Biosciences, Inc. SLDB, a gene therapy company focused on treating Duchenne muscular dystrophy (DMD ... projects toward clinical trials in 2025.